Zymeworks removes CFO; Gilead extends Nurix deal

Plus, news about Onconova Therapeutics, Trawsfynydd Therapeutics, Nocion Therapeutics, Ginkgo Bioworks and Modulus Therapeutics:

Zymeworks ousts CFO: The biotech disclosed Monday that it had removed CFO Christopher Astle on March 31, though did not provide a reason in an SEC filing. President and CEO Kenneth Galbraith is serving as interim CFO until the company finds a replacement. “Following careful consideration, and in the interest of our commitment to continuing our growth and success, the decision was made to initiate a search for a new CFO who possesses the specific experience, expertise and vision to drive our business strategies forward effectively,” a spokesperson wrote to Endpoints in an email. The company’s shares $ZYME fell about 4% on Tuesday. — Lei Lei Wu

Gilead extends Nurix deal: The company is paying $15 million to the cancer and inflammatory disease biotech…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks